Stock Pulse
Merck announced positive Phase III trial results for its new once-daily oral HIV treatment, DOR/ISL, paving the way for regulatory filings by mid-2025 [2], [5], [6]. The company also announced an upcoming dividend payment of US$0.81 per share, reflecting a healthy payout ratio and sustained earnings growth [1]. Merck recently unveiled a new $1 billion vaccine manufacturing facility in North Carolina, boosting its production capacity [3]. While facing headwinds from decreased Gardasil sales in China [8], [9], Keytruda sales remain strong [4]. Despite some analysts favoring AI stocks for higher returns [4], [7], [9], Merck's diverse portfolio, robust pipeline, and strategic investments position it for long-term growth [3], [7]. Vanguard Group increased its stake in Merck, now owning 10.02% [10].